ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301 DALLAS, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists targeting...

ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...

ImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual Biotechnology Private Company Symposium DALLAS, Sept. 16, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists...

ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301 Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...

ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...